Beta-Sitosterol (purity>80%)
Based on 22 publication(s) in Google Scholar
Beta-Sitosterol (purity≥80%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
For research use only. We do not sell to patients.
- Purity: 94.91%
- CAS No.: 83-46-5
- Formula: C29H50O
- Molecular Weight:414.71
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Beta-Sitosterol (purity>80%)
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- J Control Release. 2026 Apr 10:392:114691. [Abstract]
- Phytomedicine. 2024 Sep 7:135:156030. [Abstract]
- Int J Pharm X. 2026 Apr 13:11:100543. [Abstract]
- Phytother Res. 2026 May;40(5):2491-2513. [Abstract]
- Plant J. 2025 Nov;124(3):e70559. [Abstract]
- Acta Neuropathol Commun. 2020 Apr 22;8(1):56. [Abstract]
- J Ethnopharmacol. 2025 Sep 9;355(Pt A):120590. [Abstract]
- Biosci Rep. 2020 Oct 30;40(10):BSR20201349. [Abstract]
- Sci Rep. 2025 Jul 11;15(1):25045. [Abstract]
- Mol Med Rep. 2025 Apr;31(4):95. [Abstract]
- Front Oncol. 2022 Aug 10;12:882784. [Abstract]
- Processes (Basel). 2026 Jan;14(9):1351.
- Int J Clin Pract. 2025 Aug 25.
- Int J Environ Health Res. 2026 Feb 17:1-12. [Abstract]
- Lett Drug Des Discov. 2026 Feb 11.
- Discover Pharmaceutical Sciences. 2026 Jan 7;2(1):1.
- SSRN. 2025 May 6.
- Res Sq. 2025 May 16.
- Patent. US20240209361A1.
- Research Square Preprint. 2021. Jul.
- Evid Based Complement Alternat Med. 2020 Apr 29;2020:2760979. [Abstract]
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
WB
-
Cell Proliferation/Viability Assay
-
ELISA
All Endogenous Metabolite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 1A9 | ED50 |
10.6 μg/mL
Compound: 17
|
Cytotoxicity against human 1A9 cells after 6 days by SRB assay
Cytotoxicity against human 1A9 cells after 6 days by SRB assay
|
[PMID: 14640511] |
| 1A9 | ED50 |
16.8 μg/mL
Compound: 17
|
Cytotoxicity against human 1A9 cells after 3 days by SRB assay
Cytotoxicity against human 1A9 cells after 3 days by SRB assay
|
[PMID: 14640511] |
| 1A9/ptx-10 | ED50 |
20 μg/mL
Compound: 17
|
Cytotoxicity against human 1A9/PTX10 cells after 3 days by SRB assay
Cytotoxicity against human 1A9/PTX10 cells after 3 days by SRB assay
|
[PMID: 14640511] |
| 1A9/ptx-10 | ED50 |
9.5 μg/mL
Compound: 17
|
Cytotoxicity against human 1A9/PTX10 cells after 6 days by SRB assay
Cytotoxicity against human 1A9/PTX10 cells after 6 days by SRB assay
|
[PMID: 14640511] |
| A2780 | IC50 |
>10 μg/mL
Compound: page 1629, R26C1
|
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
|
[PMID: 17125236] |
| A549 | ED50 |
>20 μg/mL
Compound: 17
|
Cytotoxicity against human A549 cells after 3 days by SRB assay
Cytotoxicity against human A549 cells after 3 days by SRB assay
|
[PMID: 14640511] |
| A549 | IC50 |
>10 μg/mL
Compound: page 1629, R26C1
|
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 17125236] |
| Bel-7402 | IC50 |
>10 μg/mL
Compound: page 1629, R26C1
|
Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay
Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay
|
[PMID: 17125236] |
| BGC-823 | IC50 |
>10 μg/mL
Compound: page 1629, R26C1
|
Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay
Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay
|
[PMID: 17125236] |
| ECV-304 | IC50 |
472 μM
Compound: beta-sitosterol
|
Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry
Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry
|
[PMID: 22503361] |
| ECV-304 | IC50 |
472 μM
Compound: Beta-sitosterol
|
Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay
Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay
|
[PMID: 24084294] |
| ECV-304 | IC50 |
61 μM
Compound: beta-sitosterol
|
Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay
Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay
|
[PMID: 22503361] |
| ECV-304 | IC50 |
61 μM
Compound: Beta-sitosterol
|
Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay
Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay
|
[PMID: 24084294] |
| HCT-8 | ED50 |
>20 μg/mL
Compound: 17
|
Cytotoxicity against human HCT8 cells after 3 days by SRB assay
Cytotoxicity against human HCT8 cells after 3 days by SRB assay
|
[PMID: 14640511] |
| HCT-8 | IC50 |
>10 μg/mL
Compound: page 1629, R26C1
|
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
|
[PMID: 17125236] |
| HeLa | IC50 |
46.22 μM
Compound: 9
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 19447618] |
| HEp-2 | IC50 |
11.4 μM
Compound: 119
|
Antiproliferative activity against human Hep2 cells by MTT assay
Antiproliferative activity against human Hep2 cells by MTT assay
|
[PMID: 30830783] |
| HT-1080 | IC50 |
2.5 μM
Compound: Angelicin
|
Cytotoxicity against human HT1080 cells assessed as reduction in cell viability
Cytotoxicity against human HT1080 cells assessed as reduction in cell viability
|
[PMID: 30660827] |
| HUVEC | ED50 |
>5 μg/mL
Compound: beta-sitosterol
|
Cytotoxicity against HUVEC
Cytotoxicity against HUVEC
|
[PMID: 15043409] |
| J774 | IC50 |
>241.1 μM
Compound: 11
|
Cytotoxicity against mouse J774 cells by alamar blue assay
Cytotoxicity against mouse J774 cells by alamar blue assay
|
[PMID: 17637068] |
| KB | ED50 |
>20 μg/mL
Compound: 17
|
Cytotoxicity against human KB cells after 3 days by SRB assay
Cytotoxicity against human KB cells after 3 days by SRB assay
|
[PMID: 14640511] |
| KB | IC50 |
>10 μg/mL
Compound: 119
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability
Antiproliferative activity against human KB cells assessed as reduction in cell viability
|
[PMID: 30830783] |
| KB | IC50 |
>241.5 μM
Compound: 119
|
Antiproliferative activity against human KB/HeLa cells assessed as reduction in cell viability
Antiproliferative activity against human KB/HeLa cells assessed as reduction in cell viability
|
[PMID: 30830783] |
| LNCaP | ED50 |
>5 μg/mL
Compound: beta-sitosterol
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 15043409] |
| Lu1 | ED50 |
>5 μg/mL
Compound: beta-sitosterol
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 15043409] |
| MCF7 | ED50 |
>20 μg/mL
Compound: 17
|
Cytotoxicity against human MCF7 cells after 3 days by SRB assay
Cytotoxicity against human MCF7 cells after 3 days by SRB assay
|
[PMID: 14640511] |
| MCF7 | ED50 |
>5 μg/mL
Compound: beta-sitosterol
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 15043409] |
| MCF7 | IC50 |
42.1 μM
Compound: 9
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 19447618] |
| PC-3 | ED50 |
>20 μg/mL
Compound: 17
|
Cytotoxicity against human PC3 cells after 3 days by SRB assay
Cytotoxicity against human PC3 cells after 3 days by SRB assay
|
[PMID: 14640511] |
| SK-MEL-1 | IC50 |
>50 μM
Compound: 9
|
Cytotoxicity against human SK-MEL-1 cells by MTT assay
Cytotoxicity against human SK-MEL-1 cells by MTT assay
|
[PMID: 19447618] |
| U-87MG ATCC | ED50 |
>20 μg/mL
Compound: 17
|
Cytotoxicity against human U87MG cells after 3 days by SRB assay
Cytotoxicity against human U87MG cells after 3 days by SRB assay
|
[PMID: 14640511] |
| Vero | IC50 |
>128 μg/mL
Compound: 4
|
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
|
[PMID: 18818073] |
Bioactivity-guided isolation afforded three compounds from the hexane fraction of E. indica, namely, Beta-Sitosterol (β-sitosterol), Stigmasterol, and Lutein. Both compounds are found to possess very low PPL inhibition activity, that is, 2.99±0.80% (Beta-Sitosterol) of inhibition at 100 μg/mL (242 μM) and 2.68±0.38% (Stigmasterol) of inhibition at 100 μg/mL (243 μM), respectively. Weak PPL inhibition activity of Beta-Sitosterol and Stigmasterol isolated from Alpinia zerumbet with IC50 value of 99.99±1.86 μg/mL and 125.05±4.76 μg/mL, respectively, in comparison with the inhibition shown by Curcumin (IC50=4.92±0.21 μg/mL) and Quercetin (IC50=18.60±0.86 μg/mL) which are used as positive controls in their study. Beta-Sitosterol and Stigmasterol are recorded with weak PPL inhibitory activity of only 3.0±0.8% and 2.7±0.4% at 100 μg/mL, respectively, (i.e., 242 μM and 243 μM) in contrast (34.5±5.4% at 100 μg/mL), which are comparatively lower than that recorded in literature (i.e., 50% PPL inhibition at 100 μg/mL)[1]. Sitosterol is an important compound extracted from the leaves of Aloe vera. It inhibits the growth of promastigotes of L. donovani, a causative agent for life threatening visceral leishmaniasis disease[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 83-46-5
-
Appearance Solid
-
Molecular Weight 414.71
-
Formula C29H50O
-
Color White to off-white
-
SMILES
CC[C@@H](C(C)C)CC[C@@H](C)[C@H]1CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
J Control Release
Single intravitreal injection of lipid nanoparticles delivering circular mRNA of nicotinamide phosphoribosyltransferase protects against dry AMD. [Abstract]2026 Apr 10:392:114691. PMID: 41672305 -
Phytomedicine
β-sitosterol alleviates pulmonary arterial hypertension by altering smooth muscle cell phenotype and DNA damage/cGAS/STING signaling. [Abstract]2024 Sep 7:135:156030. PMID: 39265206 -
Int J Pharm X
Cutaneous delivery of bioactive components from a rice bran oil nanoemulsion and their biodistribution in porcine and human skin. [Abstract]2026 Apr 13:11:100543. PMID: 42028061 -
Phytother Res
β-Sitosterol Suppresses Osteoclastogenesis and Alleviates Bone Loss by Targeting Tmed10 to Inhibit RANKL-Induced Hedgehog/MAPK Signaling and ROS. [Abstract]2026 May;40(5):2491-2513. PMID: 41703993 -
Plant J
Unveiling the inequivalent biochemical functions of OsSMO2-1 and OsSMO2-2 in rice phytosterol biosynthesis using a customized sterol standards mixture. [Abstract]2025 Nov;124(3):e70559. PMID: 41194406 -
Acta Neuropathol Commun
Unilateral intranigral administration of β-sitosterol β-D-glucoside triggers pathological α-synuclein spreading and bilateral nigrostriatal dopaminergic neurodegeneration in the rat. [Abstract]2020 Apr 22;8(1):56. PMID: 32321590 -
J Ethnopharmacol
Ethanol extract of Liriodendron tulipifera leaves displays anti-inflammatory activity by suppressing the Syk/Src/NF-κB pathway. [Abstract]2025 Sep 9;355(Pt A):120590. PMID: 40935214 -
Biosci Rep
Experimental evidence and network pharmacology-based analysis reveal the molecular mechanism of Tongxinluo capsule administered in coronary heart diseases. [Abstract]2020 Oct 30;40(10):BSR20201349. PMID: 32990315
Beta-Sitosterol (purity>80%) purchased from MedChemExpress. Usage Cited in: Biosci Rep. 2020 Oct 30;40(10):BSR20201349. [Abstract]
Beta-sitosterol (5–100 μM; 48 h). Different concentrations of active compounds on improvement rate.
Beta-Sitosterol (purity>80%) purchased from MedChemExpress. Usage Cited in: Biosci Rep. 2020 Oct 30;40(10):BSR20201349. [Abstract]
Beta-Sitosterol (40 μM; 30 min) reduced IL-6 concentration.
-
Sci Rep
Beta sitosterol inhibits the proliferation and migration of synoviocytes in rheumatoid arthritis via lactylation of GPI. [Abstract]2025 Jul 11;15(1):25045. PMID: 40646091 -
Mol Med Rep
Mechanism of β‑sitosterol in treating keloids: Network pharmacology, molecular docking and experimental verification. [Abstract]2025 Apr;31(4):95. PMID: 39981895 -
Front Oncol
Salvia chinensis Benth Inhibits Triple-Negative Breast Cancer Progression by Inducing the DNA Damage Pathway. [Abstract]2022 Aug 10;12:882784. PMID: 36033499
Beta-Sitosterol (purity>80%) purchased from MedChemExpress. Usage Cited in: Front Oncol. 2022 Aug 10;12:882784. [Abstract]
TNBC cells were simultaneously treated with quercetin and/or β-sitosterol for 48 h. Cell viability was measured via CCK-8 assay.
Beta-Sitosterol (purity>80%) purchased from MedChemExpress. Usage Cited in: Front Oncol. 2022 Aug 10;12:882784. [Abstract]
Mice were administered β-sitosterol (75 mg/kg) each day via oral gavage. Nude mice were subcutaneously injected with MDA-MB-231 cells. Representative images showed the dissected tumors in distinct treatment groups as specified at the endpoint.
Beta-Sitosterol (purity>80%) purchased from MedChemExpress. Usage Cited in: Front Oncol. 2022 Aug 10;12:882784. [Abstract]
Mice were administered β-sitosterol (75 mg/kg) each day via oral gavage. Tumor lysates were collected, and the protein profile was established by immunoblotting analysis.
-
-
-
Int J Environ Health Res
Green extraction and RSM optimization of Peganum harmala shoots for antioxidant and anti-inflammatory properties: modulation of pro-inflammatory cytokines. [Abstract]2026 Feb 17:1-12. PMID: 41700732 -
-
-
-
-
-
-
Evid Based Complement Alternat Med
Ethanol Extract of the Infructescence of Platycarya strobilacea Sieb. et Zucc. Induces Methuosis of Human Nasopharyngeal Carcinoma Cells. [Abstract]2020 Apr 29;2020:2760979. PMID: 32419796
Solvent & Solubility
Ethanol : 4 mg/mL (9.65 mM; ultrasonic and warming and heat to 60°C)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 20 mg/mL (48.23 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Protocol
Mice[3]
Male ICR mice (20±2 g) and male KunMing mice (20±2 g) are used. Local breed, male ICR mice (20±2 g) are used in the FST under standard conditions with free access to food and water. Mice are randomly divided into four groups (8 mice per group are used) for the tail suspension test (TST): Beta-Sitosterol (10, 20, and 30 mg/kg), total sterols (50, 100, and 200 mg/kg), fluoxetine (20 mg/kg), or distilled water. 80 male mice are used. Briefly, the vehicle or test drugs are administered 30 min before a test session acute ip injection. Then, mice are individually suspended by tail with clamp (2 cm from the tip of the end) in a box (25 cm×25 cm×30 cm) with the head 5 cm to the bottom. Testing is carried out in a darkened room with minimal background noise. All animals are suspended for total 6 min, and the duration of immobility is observed and measured during the final 4-min interval of the test. All test sessions are recorded by a video camera positioned directly above the box. Two competent observers blind to treatment scored the videotapes. Mice consider immobile only when they hung passively and completely motionless. The animals are used only once in this test. All TSTs are performed between 11:00 A.M. and 14:00 P.M.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bin Sayeed MS, et al. Beta-Sitosterol: A Promising but Orphan Nutraceutical to Fight Against Cancer. Nutr Cancer. 2015;67(8):1214-20. [Content Brief]
[2]. Tariq A, et al. Ethnomedicines and anti-parasitic activities of Pakistani medicinal plants against Plasmodia and Leishmania parasites. Ann Clin Microbiol Antimicrob. 2016 Sep 20;15(1):52. [Content Brief]
[3]. Zhao D, et al. Structural Features and Potent Antidepressant Effects of Total Sterols and β-sitosterol Extracted from Sargassum horneri. Mar Drugs. 2016 Jun 28;14(7). [Content Brief]
[4]. Fan Y, et al. Beta-Sitosterol Suppresses Lipopolysaccharide-Induced Inflammation and Lipogenesis Disorder in Bovine Mammary Epithelial Cells. Int J Mol Sci. 2023 Sep 27;24(19):14644. [Content Brief]
[5]. Rajavel T, et al. Beta-Sitosterol targets Trx/Trx1 reductase to induce apoptosis in A549 cells via ROS mediated mitochondrial dysregulation and p53 activation. Sci Rep. 2018 Feb 1;8(1):2071. [Content Brief]
[6]. Liu R, et al. Beta-Sitosterol modulates macrophage polarization and attenuates rheumatoid inflammation in mice. Pharm Biol. 2019 Dec;57(1):161-168. [Content Brief]
[7]. Villaseñor IM, et al. Bioactivity studies on beta-sitosterol and its glucoside. Phytother Res. 2002 Aug;16(5):417-21. [Content Brief]
[8]. Ju YH, et al. beta-Sitosterol, beta-Sitosterol Glucoside, and a Mixture of beta-Sitosterol and beta-Sitosterol Glucoside Modulate the Growth of Estrogen-Responsive Breast Cancer Cells In Vitro and in Ovariectomized Athymic Mice. J Nutr. 2004 May;134(5):1145-51. [Content Brief]
[9]. Awad AB, et al. beta-Sitosterol activates Fas signaling in human breast cancer cells. Phytomedicine. 2007 Nov;14(11):747-54. [Content Brief]
[10]. Loizou S, et al. Beta-sitosterol exhibits anti-inflammatory activity in human aortic endothelial cells. Mol Nutr Food Res. 2010 Apr;54(4):551-8. [Content Brief]
[11]. Vivancos M, et al. beta-Sitosterol modulates antioxidant enzyme response in RAW 264.7 macrophages. Free Radic Biol Med. 2005 Jul 1;39(1):91-7. [Content Brief]
[12]. Gupta R, et al. Antidiabetic and antioxidant potential of Beta-Sitosterol in streptozotocin-induced experimental hyperglycemia. J Diabetes. 2011 Mar;3(1):29-37. [Content Brief]
[13]. Anwar R, et al. Antimicrobial Activity of Beta-Sitosterol Isolated from Kalanchoe tomentosa Leaves Against Staphylococcus aureus and Klebsiella pneumonia. Pak J Biol Sci. 2022 Jun;25(7):602-607. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.4113 mL | 12.0566 mL | 24.1132 mL | 60.2831 mL |
| 5 mM | 0.4823 mL | 2.4113 mL | 4.8226 mL | 12.0566 mL |